Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
212.3 USD | +1.38% | +1.79% | -15.61% |
May. 08 | Morgan Stanley Cuts Price Target on Penumbra to $235 From $240, Keeps Equalweight Rating | MT |
May. 07 | Penumbra Q1 Non-GAAP EPS, Revenue Increase; Reaffirms 2024 Revenue Outlook | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- Growth is a substantial asset for the company, as anticipated by dedicated analysts. Within the next three years, growth is estimated to reach 57% by 2026.
- The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
- The company is in a robust financial situation considering its net cash and margin position.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
Weaknesses
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 77.21 times its estimated earnings per share for the ongoing year.
- Based on current prices, the company has particularly high valuation levels.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The valuation of the company is particularly high given the cash flows generated by its activity.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-15.61% | 8.23B | C+ | ||
+73.46% | 12.41B | B- | ||
+3.88% | 6.46B | C- | ||
+14.69% | 5.5B | D+ | ||
-5.53% | 5.33B | B | ||
+42.58% | 5.1B | - | ||
-32.61% | 2.54B | C | ||
+10.80% | 1.99B | - | ||
-0.74% | 1.99B | - | ||
+10.31% | 1.77B | C- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- PEN Stock
- Ratings Penumbra, Inc.